ARTICLE | Finance
VC pair seeds cancer play Yukin, seeks preclinical readout
Advent and Medicxi want to see a differentiated program for French newco Yukin’s kinase inhibitors targeting the NIK protein
June 21, 2019 9:18 PM UTC
While Advent France Biotechnology and Medicxi are taking a wait-and-see approach with Yukin's kinase inhibitors targeting the NIK protein for cancer, the firms believe they could follow the biotech's €3.3 million ($3.7 million) seed round with a larger series A round within a year.
Co-founded last year by Advent and technology transfer office SATT Sud-Est, Nice-based Yukin Therapeutics is building programs based on research from scientific co-founders Thierry Passeron of the Mediterranean Center for Molecular Medicine (C3M) and Rachid Benhida of the Institute of Chemistry of Nice (ICN)...